What if radiation could become one of the most precise medicines ever invented? Long before radiopharmaceuticals became one of the hottest areas in biotech, today's guest was helping pioneer targeted radiation therapies that seek out cancer cells while minimizing damage to healthy tissue. Today, the field is attracting billions in investment and reshaping oncology.
Our guest today is one of the true pioneers of modern targeted radiopharmaceutical therapy.
Dr. Ebrahim Delpassand, MD is the Founder, Chairman and CEO of RadioMedix ( https://radiomedix.com/ ), a clinical-stage biotechnology company developing next-generation targeted radioactive diagnostics and therapeutics for cancer.
Long before radiopharmaceuticals became one of the most exciting areas in precision oncology, Dr. Delpassand was introducing these therapies to patients who had exhausted every other option.
As former Deputy Chairman and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center, Dr. Delpassand served as Principal Investigator on some of the very first FDA Investigational New Drug programs for Lutetium-177 therapies in the United States, including the nation's first INDs for Lu-177 DOTATATE peptide receptor radionuclide therapy and Lu-177 PSMA-617 therapy.
Board-certified in Nuclear Medicine and trained in both pathology and nuclear medicine at Baylor College of Medicine, Dr. Delpassand has authored more than ninety peer-reviewed publications and has spent decades advancing therapeutic nuclear medicine through research, clinical care, and education.
But perhaps even more remarkable is his entrepreneurial journey. Nearly twenty years ago, convinced that targeted radiopharmaceuticals represented a fundamentally new way to fight cancer, Dr. Delpassand founded RadioMedix and personally sustained the company through its earliest years while helping build not only innovative therapies, but also isotope production capabilities, cGMP manufacturing infrastructure, and broader access to these life-saving treatments.
Today, as radiotheranostics transforms cancer care around the world, Dr. Delpassand joins us to discuss where the field began, where it is heading, and what the next generation of precision radiation medicines could mean for patients.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ira Pastor. Innehållet i podden är skapat av Ira Pastor och inte av,
eller tillsammans med, Poddtoppen.
